


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof:



wherein A represents oxygen, ~~sulfur or a group represented by the formula >NR<sup>3</sup> (wherein R<sup>3</sup> represents hydrogen atom or a lower alkyl group)~~; R<sup>1</sup> represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5-6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen ~~and or~~ C<sub>1-6</sub> ~~allyl~~ alkyl groups; R<sup>2</sup> represents an optionally substituted aryl group, a


1-9 membered heteroarylalkyl having 1-4 heteroatoms, an optionally substituted heteroaryl group that is formed from one or two 5-6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and R<sup>4</sup> and R<sup>5</sup> are the same as or different from each other and each represents hydrogen atom, hydroxyl group, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, provided that A is an oxygen atom, when R<sup>1</sup> and R<sup>2</sup> are both phenyl; and

when A is a sulfur atom, R<sup>1</sup> is an aryl which may have a substituent, a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms, an alkyl which may have a substituent, a heteroarylalkyl which may have a substituent,

~~an arylalkenyl which may have a substituent,~~  
~~a heteroarylalkenyl which may have a substituent,~~  
~~a piperidyl which may have a substituent,~~  
~~a piperadiny1 which may have a substituent,~~  
~~a morpholinyl which may have a substituent,~~  
~~a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,~~  
~~tetrahydrofuranly,~~  
~~adamantyl or~~

04 ~~an optionally substituted amide, that is CO N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and~~

provided that the compounds represented by the following formula (II):



(wherein R<sup>11</sup> and R<sup>12</sup> are the same as or different from each other and each represents hydrogen atom, fluorine, chlorine, bromine, iodine, a C1-C2 fluoroalkyl group, a C1-C2 chloroalkyl group, a C1-C2 bromoalkyl group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C7-C9 aralkyl group, phenyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group, a C1-C6 alkylsulfinyl group, a C7-C9 aralkoxy

04 group, phenoxy group, phenylthio group, phenylsulfonyl group, an alkali metal carboxylate C2-C5 alkoxy carbonyl group or a group represented by the formula  $-N(R^{15})R^{16}$  (wherein  $R^{15}$  and  $R^{16}$  are the same as or different from each other and each represents hydrogen atom or a C1-C2 alkyl group); and  $R^{13}$  and  $R^{14}$  are the same as or different from each other and each represents a C<sub>1-4</sub> alkylsulfonyl group, nitro group, a group represented by the formula  $-OCH_nX_{3-n}$  (wherein X represents fluorine, chlorine, bromine or iodine; and n is an integer of 1 to 3) or the same groups as defined above for  $R^{11}$  and  $R^{12}$ ) are excluded.

2. (Previously Amended) The compound according to claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein  $R^4$  and  $R^5$  are the same as or different from each other and each represents hydrogen atom, hydroxyl group, a C<sub>1-6</sub> alkyl group or an aryl group.


3. (Previously Amended) The compound according to claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein  $R^4$  is hydrogen atom and  $R^5$  is hydroxyl group, a C<sub>1-6</sub> alkyl group or an aryl group.

4. (Previously Amended) The compound according to claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R<sup>4</sup> is hydrogen atom and R<sup>5</sup> is hydroxyl group, methyl group, ethyl group, n-propyl group, i-propyl group or phenyl group.

04 5. (Previously Amended) The compound according to claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R<sup>4</sup> and R<sup>5</sup> are the same as or different from each other and each represents methyl group, ethyl group, n-propyl group or i-propyl group.

6. (Previously Amended) The compound according to claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein A is oxygen.

7. (Previously Amended) The compound according to claim 1, wherein R<sup>4</sup> and R<sup>5</sup> are hydrogen and which is represented by the following formula (III):



(wherein A, R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined in claim 1), a pharmacologically acceptable salt thereof or hydrates thereof.

8. (Previously Amended) The compound according to claim 7, a pharmacologically acceptable salt thereof or hydrates thereof, wherein  $R^1$  is an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, a morpholinyl group, a lower  $C_{3-8}$  cycloalkyl group, an optionally substituted amino group or an optically substituted amide group that is  $CO-N(R_a)R_b$ , wherein  $R_a$  and  $R_b$  are hydrogen and  $C_{1-6}$  alkyl group; and  $R^2$  is an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, a lower  $C_{3-8}$  cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an optionally substituted piperidyl group or an adamantyl group.

9. (Previously Amended) The compound according to claim 7 or 8, a pharmacologically acceptable salt thereof or hydrates thereof, wherein the substituent groups on  $R^1$  and  $R^2$  are hydrogen atom, halogen atom, hydroxyl group, lower alkyl group, lower alkenyl


group, lower alkynyl group, lower alkoxy group, lower thioalkoxy group, hydroxy lower thioalkoxy group, arylthio group, heteroaryl thio group, heteroaryl(hydroxy)alkyl group, halogenated lower alkyl group, hydroxy lower alkyl group, dihydroxy lower alkyl group, halogenated (hydroxy) lower alkyl group, hydroxyalkenyl group, hydroxyalkynyl group, hydroxy lower cycloalkenyl group, lower alkoxy(hydroxy)alkyl group, lower alkoxy(hydroxy)alkoxy group, lower alkoxy alkyl group, lower alkoxy alkoxy group, lower thioalkoxy alkoxy group, lower alkyl sulfonyl alkoxy group, hydroxy lower alkoxy group, dihydroxy lower alkoxy group, hydroxy lower alkyl alkoxy group, hydroxy imino lower alkyl group, lower cycloalkyl(hydroxy)alkyl group, aralkyl group, hydroxyaralkyl group, cyano group, cyano lower alkyl group, amide group that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen or C<sub>1-6</sub> alkyl group, N-lower alkyl amide group, N-lower cycloalkyl amide group, N,N-di-lower alkyl amide group, N-hydroxy lower alkyl amide group, N-hydroxy lower alkyl-N-lower alkyl amide group, N-aryl amide group, cyclic aminocarbonyl group, carbamoyl group, N-lower alkyl carbamoyl group, N,N-di-lower alkyl carbamoyl group, aminosulfonyl group, cyclic aminosulfonyl group, N-lower alkyl aminosulfonyl group, N-lower cycloalkyl aminosulfonyl group, N,N-di-lower alkyl aminosulfonyl group, N-hydroxy lower alkyl aminosulfonyl group, N-lower alkoxy alkyl aminosulfonyl group, N-halogenated lower alkyl

sulfonyl group, pyrrolidinyl sulfonyl group, lower alkyl sulfonyl amino alkyl group, N-lower alkyl aminosulfonyl alkyl group, N,N-di-lower alkyl aminosulfonyl alkyl group, lower acyl group, lower acyl alkyl group, lower cycloalkyl(hydroxy)methyl group, tetrahydropyranyl group, hydroxytetrahydropyranyl group, hydroxy lower alkyl tetrahydropyranyl group, lower acyl amino alkyl group, (thiazole-2-yl)hydroxymethyl group, di(thiazole-2-yl)hydroxymethyl group, lower alkyl sulfonyl group, lower alkoxy alkyl sulfonyl group, hydroxy lower alkyl sulfonyl group, lower alkyl sulfonyl alkyl group, N-lower alkyl amide alkyl group, aryl group, aralkyl group, heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, heteroaryl lower alkyl group, heteroaryl lower alkoxy group, heteroaryl sulfonyl group, 4-morpholinyl sulfonyl group, 4-oxythiomorpholinyl sulfonyl group, 4-dioxythiomorpholinyl sulfonyl group, 4-morpholinyl sulfonyl group, hydroxy lower cycloalkyl group, hydroxy lower cycloalkyloxy group, hydroxy cycloalkenyl group, halogenated hydroxy lower alkyl group, 4-hydroxypiperidyl group, 4-lower alkoxypiperidyl group, ω,ω-lower alkylene dioxyalkyl group, ω,ω-lower alkylene dioxy alkoxy group, lower cycloalkyl hydroxy methyl group, aryloxy group, aryl aminosulfonyl group, amino group, lower alkyl amino group, di-lower alkyl amino group, hydroxy lower alkyl amino group, lower acyl amino group, hydroxy lower acyl amino



group, lower alkyl sulfonyl amino group, pyridyl lower alkoxy group, lower alkyl pyridyl alkoxy group, lower alkoxy hydroxy alkoxy group, lower thioalkoxy alkoxy group, lower alkyl sulfonyl alkoxy group, N-lower alkyl carbamoyl group, N,N-di-lower alkyl carbamoyl group, N-hydroxy lower alkyl carbamoyl group, N-hydroxy lower alkyl-N-lower alkyl carbamoyl group, halogenated lower alkoxy group, cyano lower alkoxy group, hydroxy lower cycloalkoxy group, trifluoromethyl group, trifluoromethoxy group, amino lower alkoxy group, N-lower alkyl aminoalkoxy group, N,N-di-lower alkyl aminoalkoxy group, lower acyl alkoxy group, lower acyl aminoalkoxy group, (1,3-dioxolanyl) lower alkyl group, (1,3-dioxolanyl) lower alkoxy group, amide lower alkoxy group, 4-(hydroxy alkyl)tetrahydro-pyran-4-yl group, 2,3-dihydrobenzofuranyl group, 2-hydroxy-2-alkyl-2,3-dihydrobenzofuranyl group, indanonyl group, hydroxyindanyl group, imidazolyl lower alkoxy group, succimide group or 2-oxazolidone-3-yl group, optionally substituted benzoyloxy lower alkyl group, optionally substituted amino lower alkyl group, optionally substituted amino lower alkoxy group, optionally substituted aralkyloxy group, optionally substituted heteroaryl alkoxy group, optionally substituted morpholinyl lower alkoxy group, optionally substituted piperidyl lower alkoxy group, optionally substituted piperazinyl lower alkoxy group or optionally substituted pyrrolidinyl lower alkoxy group.

10. (Previously Amended) The compound according to claim 7, represented by the following formula (IV):



(wherein R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined in claim 7), a pharmacologically acceptable salt thereof or hydrates thereof.

11. (Previously Amended) The compound according to claim 7, a pharmacologically acceptable salt thereof or hydrates thereof, wherein the aryl group is a group selected from phenyl group, indenyl group, naphthyl group, azulenyl group, heptalenyl group and anthnyl group; the heteroaryl group is a group selected form thienyl group, furyl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, triazolyl group, tetrazolyl group, isothiazolyl group, thiazolyl group, thiadiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidyl group, pyridazinyl group, indoliziny group, isoindolyl group, indolyl group, indazolyl group, isoquinolyl group, quinolyl group, phthalazinyl group, naphthylidiny group, quinoxaliny group, quinazoliny group and cinolynyl group; and the lower cycloalkyl group is a group selected from cyclopropyl group, cyclobutyl group,

cyclopentyl group, cyclohexyl group, cycloheptyl group and cyclooctyl group.

12. (Previously Amended) The compound according to claim 7, which is the compound selected from the following compounds or pharmacologically acceptable salts thereof or hydrates thereof:

- 04
- (1) 2-(2-Pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (2) 2-(2-pyrazinyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (3) 2-(1-methyl-2-pyrrolyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (4) 2,4-diphenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (5) 2-(2,3-dimethoxyphenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (6) 2-(2-pyrrolyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (7) 2-(2-quinolyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (8) 2-(6-methyl-2-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (9) 2-benzoyloxymethyl-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (10) 2-(2-pyridyl)-4-(2,4-difluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
  - (11) 2-(2-pyridyl)-4-cyclohexyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (12) 2-(2-chloro-4-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
  - (13) 2-(3-methoxy-2-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

- (14) 2-(3-hydroxy-2-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (15) 2-styryl-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (16) 2-[2-(3-pyridyl)vinyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (17) 2-(2-methoxyphenyl)-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (18) 2-(4-nitrophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (19) 2-(3-nitrophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (20) 2-(2-nitrophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (21) 2-(4-morpholinyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (22) 2-cyclohexyl-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (23) 2-dimethylamino-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (24) 2-dimethylamino-4-phenyl-4H-1,3,4-thiadiazine-5(6H)-one,
- (25) 2-(2,6-dimethoxyphenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (26) 2-(2-methoxyphenyl)-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (27) 2-phenyl-4-cyclohexyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (28) 2-(2-methoxyphenyl)-4-cyclohexyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (29) 2-(3-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (30) 2-phenyl-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,

- (31) 2-(2-thienyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (32) 2-benzyl-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (33) 2-(2-pyridyl)-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (34) 2-(2-pyridyl)-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (35) 2-(2-pyridyl)-4-(2-methoxyphenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- 14 (36) 2-phenyl-4-(2-cyanophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (37) 2-phenyl-4-(2-nitrophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (38) 2-phenyl-4-(2-pyridyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (39) 2-phenyl-4-(3-pyridyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (40) 2-phenyl-4-(3-cyano-2-pyridyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (41) 2-phenyl-4-(2-hydroxymethylphenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (42) 2-phenyl-4-(2-cyano-3-pyridyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (43) 2-phenyl-4-(2-thienyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (44) 2-phenyl-4-(3-thienyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (45) 2-phenyl-4-(4-cyanophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (46) 2-phenyl-4-(3-cyanophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,

- (47) 2-phenyl-4-(2-cyano-3-thienyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (48) 2-(2-hydroxyphenyl)-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (49) 2-(2-hydroxyphenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (50) 2-phenyl-4-(2-hydroxyphenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (51) 2-(2-hydroxyphenyl)-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- 104 (52) 2-(2-hydroxyphenyl)-4-(4-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (53) 2-(2-hydroxyphenyl)-4-(2,4-difluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (54) 2-[2-(2-dimethylamino)ethoxyphenyl]-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (55) 2-[2-(4-pyridyl)methoxyphenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (56) 2-{2-[2-(4-morpholinyl)ethoxy]phenyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (57) 2-[2-(2-pyridyl)methoxyphenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (58) 2-[2-(3-pyridyl)methoxyphenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

- 04
- (59) 2-{2-[2-(1-piperidyl)ethoxy]phenyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (60) 2-{2-[2-(1-pyrrolidinyl)ethoxy]phenyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (61) 2-[2-(2-dimethylaminoethoxy)phenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (62) 2-[2-(3-dimethylaminopropoxy)phenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (63) 2-{2-[3-(1-piperidinyl)propoxy]phenyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,
- (64) 2-phenyl-{4-[2-(4-morpholinyl)ethoxy]phenyl}-4H-1,3,4-oxadiazine-5(6H)-one,
- (65) 2-phenyl-4-[2-(2-dimethylaminoethoxy)phenyl]-4H-1,3,4-oxadiazine-5(6H)-one,
- (66) 2-[2-(2-dimethylaminoethoxy)phenyl]-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (67) 2-{2-[2-(4-morpholinyl)ethoxy]phenyl}-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (68) 2-{2-[2-(4-morpholinyl)ethoxy]phenyl}-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,
- (69) 2-{2-[2-(4-morpholinyl)ethoxy]phenyl}-4-cyclohexyl-4H-1,3,4-oxadiazine-5(6H)-one,

(70) 2-{2-[2-(4-morpholinyl)ethoxy]phenyl}-4-(4-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,

(71) 2-{2-[2-(4-morpholinyl)ethoxy]phenyl}-4-(2,4-difluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one,

(72) 2-[3-(2-hydroxyethoxy)-2-pyridyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(73) 2-{3-[2-(4-morpholinyl)ethoxy]-2-pyridyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

104 (74) 2-{3-[2-(1-piperidyl)ethoxy]-2-pyridyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(75) 2-{3-[2-(1-pyrrolidinyl)ethoxy]-2-pyridyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(76) 2-{3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-2-pyridyl}-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(77) 2-[3-(2-dimethylaminoethoxy)-2-pyridyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(78) 2-(3-aminophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(79) 2-(2-aminophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(80) 2-phenyl-4-(tetrahydro-4H-pyran-4-yl)-4H-1,3,4-oxadiazine-5(6H)-one,

(81) 2-phenyl-4-(1-methyl-4-piperidyl)-4H-1,3,4-oxadiazine-5(6H)-one,

(82) 2-phenyl-4-(3-quinuclidinyl)-4H-1,3,4-oxadiazine-5(6H)-one,



(83) 2-pyridyl-4-(1-benzyl-4-piperidyl)-4H-1,3,4-oxadiazine-5(6H)-one,

(84) 2-phenyl-4-(3-tetrahydrofuranyl)-4H-1,3,4-oxadiazine-5(6H)-one,

(85) 2-phenyl-4-cyclopentyl-4H-1,3,4-oxadiazine-5(6H)-one,

(86) 2-phenyl-4-(1-benzyl-4-piperidyl)-4H-1,3,4-oxadiazine-5(6H)-one,

(87) 2-phenyl-4-[1-(2-pyridyl)ethyl]-4H-1,3,4-oxadiazine-5(6H)-one,

(88) 2-phenyl-4-[1-(3-pyridyl)ethyl]-4H-1,3,4-oxadiazine-5(6H)-one,

(89) 2-phenyl-4-[1-(4-pyridyl)ethyl]-4H-1,3,4-oxadiazine-5(6H)-one,

(90) 2-(3-dimethylaminophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(91) 2-(2-dimethylaminophenyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(92) 2-[2-(4-pyridyl)methylaminophenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(93) 2-[2-(3-pyridyl)methylaminophenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(94) 2-(4-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one,

(95) N-(2-pyridyl)-[4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one-2-yl]carboxamide,


(96) N-(3-pyridyl)-[4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one-2-yl]carboxamide,

(97) N-(4-pyridyl)-[4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one-2-yl]carboxamide,

(98) 1,3-diphenyl-4-methyl-4,5-dihydro-1,2,4-triazine-6(1H)-one and

(99) 1-phenyl-3-(2-pyridyl)-4-methyl-4,5-dihydro-1,2,4-triazine-6(1H)-one.

13. (Previously Amended) A pharmaceutical composition comprising a pharmacologically acceptable amount of the compound represented by the following formula (I), a pharmaceutically acceptable salt thereof or hydrates thereof, and pharmacologically acceptable carriers:



wherein A represents oxygen, sulfur or a group represented by the formula  $>NR^3$  (wherein  $R^3$  represents hydrogen atom or a lower alkyl group);  $R^1$  and  $R^2$  are the same as or different from each other and each represents an optionally substituted aryl group, an

optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and R<sup>4</sup> and R<sup>5</sup> are the same as or different from each other and each represents hydrogen atom, hydroxyl group, halogen atom, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms

provided that A is an oxygen atom, when R<sup>1</sup> and R<sup>2</sup> are both phenyl; and

when A is a sulfur atom, R<sup>1</sup> is

an aryl which may have a substituent,


a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms,

an aralkyl which may have a substituent,

a heteroarylalkyl which may have a substituent  
 an arylalkenyl which may have a substituent,  
 a heteroarylalkenyl which may have a substituent,  
 a piperidyl which may have a substituent,  
 a piperadinyll which may have a substituent,  
 a morpholinyl which may have a substituent,  
 a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,  
 tetrahydrofuranyl,  
 adamantyl or


an optionally substituted amide, that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group.

14. (Original) The pharmaceutical composition according to claim 13, wherein R<sup>4</sup> and R<sup>5</sup> in the compound are hydrogen atoms, and the compound is represented by the following formula (V):



wherein A, R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined above.

15. (Previously Amended) A pharmaceutical preparation comprising the compound represented by the following formula (I), a pharmaceutically acceptable salt thereof or hydrates thereof:



04 wherein A represents oxygen, sulfur or a group represented by the formula  $>NR^3$  (wherein  $R^3$  represents hydrogen atom or a lower alkyl group);  $R^1$  and  $R^2$  are the same as or different from each other and each represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5-6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower  $C_{3-8}$  cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is  $-CO-N(R_a)R_b$ , wherein  $R_a$  and  $R_b$  are hydrogen or  $C_{1-6}$  alkyl group; and  $R^4$  and  $R^5$  are the same as or different from each other

and each represents hydrogen atom, hydroxyl group, a halogen atom, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms

provided that A is an oxygen atom, when R<sup>1</sup> and R<sup>2</sup> are both phenyl; and

when A is a sulfur atom, R<sup>1</sup> is

an aryl which may have a substituent,

04 a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms,

an aralkyl which may have a substituent,

a heteroarylalkyl which may have a substituent,

an arylalkenyl which may have a substituent,

a heteroarylalkenyl which may have a substituent,

a piperidyl which may have a substituent,

a piperadinyll which may have a substituent,

a morpholinyl which may have a substituent,


a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,

tetrahydrofuranyl,

adamantyl or

an optionally substituted amide, that is -CO-N(Ra)Rb, wherein Ra and Rb are hydrogen and C<sub>1-6</sub> alkyl group.

16. (Original) The pharmaceutical preparation according to claim 15, wherein R<sup>4</sup> and R<sup>5</sup> in the compound are hydrogen atoms, and the compound is represented by formula (V):



04 wherein A, R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined above.

17-23. (Previously Canceled)


24. (Previously Amended) A method of treating and ameliorating nerve degeneration diseases, which comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 15 or 16 to a patient.

25. (Previously Amended) A method of treating and ameliorating demyelinating nerve diseases, which comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 15 or 16 to a patient.

26. (Previously Amended) A method of treating and ameliorating acute nerve degeneration after cerebral ischemia, traumas in the head and spinal injuries, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's chorea, epilepsy, pain, multiple sclerosis, encephalomyelitis, Guillain Barre syndrome, Marchiafava Bignami disease, Devic disease, Balo disease, HIV or HTLV myelopathy or leukoencephalopathy, which comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 15 or 16 to a patient.

27. - 31. Canceled.

32. (Previously Added) A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof:






wherein A represents oxygen, sulfur or a group represented by the formula  $>NR^3$  (wherein  $R^3$  represents hydrogen atom or a lower alkyl group);  $R^1$  represents an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group;  $R^2$  represents an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aralkyl group wherein it is not benzyl, an optionally substituted heteroarylalkyl group wherein it is not pyrimidinyl alkyl, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group; and  $R^4$  and  $R^5$  are the same as or different from each other and each

represents hydrogen atom, hydroxyl group, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group,

provided that the compounds represented by the following formula (II):



(wherein  $R^{11}$  and  $R^{12}$  are the same as or different from each other and each represents hydrogen atom, fluorine, chlorine, bromine, iodine, a C1-C2 fluoroalkyl group, a C1-C2 chloroalkyl group, a C1-C2 bromoalkyl group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C7-C9 aralkyl group, phenyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group, a C1-C6 alkylsulfinyl group, a C7-C9 aralkoxy group, phenoxy group, phenylthio group, phenylsulfonyl group, an alkali metal carboxylate C2-C5 alkoxy carbonyl group or a group represented by the formula  $-N(R^{15})R^{16}$  (wherein  $R^{15}$  and  $R^{16}$  are the same as or different from each other and each represents hydrogen atom or a C1-C2 alkyl group); and  $R^{13}$  and  $R^{14}$  are the same as or different from each other and each represents a C<sub>1-4</sub> alkylsulfonyl group, nitro group, a group represented by the formula  $-OCH_nX_{3-n}$  (wherein X represents fluorine, chlorine, bromine or iodine; and n

is an integer of 1 to 3) or the same groups as defined above for  $R^{11}$

04 and  $R^{12}$ ) are excluded.

33. (Canceled)

---